---
figid: PMC5398990__13311_2017_518_Fig3_HTML
figlink: /pmc/articles/PMC5398990/figure/Fig3/
number: F3
caption: Schematic overview of underlying pathophysiology and targeted therapies in
  neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs).
  MPNSTs arise from plexiform neurofibromas (pNFs) via a stepwise malignant transformation
  process that includes the loss of NF1 (gray box), deletion of CDKN2A, and loss of
  TP53 and PRC2. The hyperactivation of the Ras pathway and acquired epigenetic alterations
  provide therapeutic targets for various molecule inhibitors (yellow boxes) GPCR
  = G-protein coupled receptor; RTK = receptor tyrosine kinase; HSP = heat shock protein;
  MEK = mitogen-activated protein kinase; ERK = extracelluar regulated kinase; PI3K
  = phosphatidylinositol 3-kinase; AKT = protein kinase B; mTOR = mammalian target
  of rapamycin; AURKA = Aurora kinase A; BET = bromodomain and extraterminal; PRC2
  = polycomb repressive complex 2; aNF = atypical neurofibroma; pNF = plexiform neurofibroma
pmcid: PMC5398990
papertitle: Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.
reftext: Verena Staedtke, et al. Neurotherapeutics. 2017 Apr;14(2):298-306.
pmc_ranked_result_index: '200193'
pathway_score: 0.9617926
filename: 13311_2017_518_Fig3_HTML.jpg
figtitle: Schematic overview of underlying pathophysiology and targeted therapies
  in neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors
  (MPNSTs)
year: '2017'
organisms: Homo sapiens
ndex: 0fb604eb-dec2-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5398990__13311_2017_518_Fig3_HTML.html
  '@type': Dataset
  description: Schematic overview of underlying pathophysiology and targeted therapies
    in neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors
    (MPNSTs). MPNSTs arise from plexiform neurofibromas (pNFs) via a stepwise malignant
    transformation process that includes the loss of NF1 (gray box), deletion of CDKN2A,
    and loss of TP53 and PRC2. The hyperactivation of the Ras pathway and acquired
    epigenetic alterations provide therapeutic targets for various molecule inhibitors
    (yellow boxes) GPCR = G-protein coupled receptor; RTK = receptor tyrosine kinase;
    HSP = heat shock protein; MEK = mitogen-activated protein kinase; ERK = extracelluar
    regulated kinase; PI3K = phosphatidylinositol 3-kinase; AKT = protein kinase B;
    mTOR = mammalian target of rapamycin; AURKA = Aurora kinase A; BET = bromodomain
    and extraterminal; PRC2 = polycomb repressive complex 2; aNF = atypical neurofibroma;
    pNF = plexiform neurofibroma
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDKN2A
  - MAPK1
  - AKT1
  - MAP2K1
  - MAPK3
  - NMUR1
  - DNER
  - AKT2
  - KRAS
  - MAP2K2
  - MTOR
  - TP53
  - AKT3
  - HESX1
  - AURKA
  - NF1
  - BRAF
  - HRAS
  - RAF1
  - NRAS
  - ARAF
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: CDKN2A
  symbol: CDKN2A
  source: hgnc_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: GPCR
  symbol: GPC-R
  source: hgnc_alias_symbol
  hgnc_symbol: NMUR1
  entrez: '10316'
- word: BET
  symbol: bet
  source: hgnc_alias_symbol
  hgnc_symbol: DNER
  entrez: '92737'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: aNF
  symbol: ANF
  source: hgnc_alias_symbol
  hgnc_symbol: HESX1
  entrez: '8820'
- word: AURKA
  symbol: AURKA
  source: hgnc_symbol
  hgnc_symbol: AURKA
  entrez: '6790'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5398990__F3
redirect_from: /figures/PMC5398990__F3
figtype: Figure
---
